DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera, Medical Writer. Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, January 2017.
Dupilumab (Dupixent®; Sanofi, Paris, France; Regeneron, New York, USA) is a fully human monoclonal antibody, which has shown significant efficacy and a favourable safety profile in moderate-to-severe atopic dermatitis alone and in combination with topical corticosteroids.
The U.S. Food and Drug Administration (FDA) approved Dupixent® as a treatment for moderate-to-severe atopic dermatitis in adults in March 2017 and in patients aged 12 to 17 in March 2019. It was approved by Therapeutic Goods Administration (TGA) in Australia in January 2018, and it was classified as a prescription medicine by Medsafe in New Zealand in March 2018.
The Biologics License Application (BLA) for dupilumab contains data from three pivotal phase 3 clinical studies evaluating dupilumab as monotherapy and in concomitant administration with topical corticosteroids.
Severe atopic dermatitis in adults
Most common (> 5%) adverse reactions associated with dupilumab treatment in clinical trials were:
No drug-specific blood-test monitoring is required.
Rarely, induction of another skin disorder has been reported, such as psoriasis.
Mild conjunctivitis is managed with lubricating eye drops. Patients on dupilumab should be advised to use these from the onset of treatment to prevent ocular symptoms. Some patients may require other treatment.
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.